Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Rapt Therapeutics has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Rapt Therapeutics's investors include Kleiner Perkins, Perceptive Advisors, Foresite Capital, Redmile Group, TCG Crossover.
Rapt Therapeutics is headquartered in South San Francisco, United States.
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Rapt Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rapt Therapeutics — Funding & Investors." VCBacked, October 21, 2025, https://www.vcbacked.co/company/rapt-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Rapt Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rapt-therapeutics
{{cite web |title=Rapt Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rapt-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated